Type 1 Diabetes Mellitus
706
58
85
475
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
178 trials with published results (25%)
Research Maturity
475 completed trials (67% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.2%
44 terminated out of 706 trials
91.5%
+5.0% vs benchmark
14%
98 trials in Phase 3/4
37%
178 of 475 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 475 completed trials
Clinical Trials (706)
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
"Ultrasound-Enhanced Propolis Therapy for Healing Diabetic Foot Wounds"
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
Societal Burden Associated With Type 1 Diabetes in Canada
Dapagliflozin Plus Pioglitazone in T1DM
AI-Assisted Remote Insulin Pump Optimization in T1DM
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
Siplizumab in T1DM
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes
Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 Diabetes
Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D
Real-world Effectiveness and Safety of Omnipod 5 in Adults With Type 1 Diabetes: a 12-month Observational Study.
CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes